[ad_1]
(HealthDay) – Initiation of glucose-cotransporter-2 (SGLT-2) sodium inhibitor therapy for type 2 diabetes is not badociated with an increased risk of developing urinary tract infections (UTIs) compared to other second-line antidiabetic drugs. , according to a study published online July 30 in the Annals of Internal Medicine.
Chintan V. Dave, Ph.D., Ph.D., of Brigham and Women's Boston Hospital, and colleagues compared the risk of occurrence of severe urinary tract infection in patients in early clinical practice the use of an SGLT-2 inhibitor compared to those beginning with the use of dipeptidyl peptidase-4 inhibitors (DPP-4) or peptide-1 receptor agonists ( GLP-1) resembling glucagon. In each of the two large US commercial claim databases, two cohorts were created and matched at a 1: 1 propensity ratio. Cohort 1 patients began using SGLT-2 inhibitors versus inhibitors. DPP-4 (123,752 patients) and those in cohort 2 were beginning to use SGLT-2 inhibitors compared to GLP-1 agonists (111,978 patients).
The researchers found that people recently receiving an SGLT-2 inhibitor experienced 61 events of severe urinary tract infection (rate of incidence). [IR] per 1,000 person-years, 1.76) versus 57 events in the group of PPD-4 inhibitors (IR, 1.77, relative risk, 0.98, 95% confidence interval, 0.68 to 1 , 41) in cohort 1. Those receiving SGLT-2 inhibitors in cohort 2 had 73 events compared to 87 events in the agonist group of GLP-1 (IR, 2.15 vs. 2.96, risk ratio 0). , 72, 95% confidence interval, 0.53 to 0.99). The researchers noted that the results were robust for all sensitivity badyzes.
"Factors other than the risk of urinary tract infection events must be taken into account in the decision to prescribe SGLT-2 treatment to diabetic patients in routine care settings," the authors write.
Several authors have revealed financial links with the pharmaceutical industry.
Higher risk of amputation, DKA with SGLT2 inhibitors for T2D
Summary / Full text (subscription or payment may be required)
Editorial (a subscription or payment may be required)
Copyright © 2019 HealthDay. All rights reserved.
Quote:
The use of SGLT-2 inhibitors is not related to an increased risk of events of urinary tract infection (2019, July 30)
recovered on July 30, 2019
from https://medicalxpress.com/news/2019-07-sglt-inhibitor-linked-uti-events.html
This document is subject to copyright. Apart from any fair use for study or private research purposes, no
part may be reproduced without written permission. Content is provided for information only.
[ad_2]
Source link
